ClinicalTrials.gg
CompletedNCT05449535Updated Jun 27, 2023

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects

A Phase 1 interventional study of JYB1904 and Omalizumab in Healthy, sponsored by Jemincare. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-27.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This phase Ia study is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904, an anti-immunoglobulin E (IgE) antibody, in healthy Chinese subjects.

Read the detailed description

This first-in-human study with a dose-escalation design is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904 in healthy Chinese subjects.

The sequential dose levels (sample size) of JYB1904 are set at five different dose, with additional two JYB1904 placebo subjects in each group. The active comparator is omalizumab (Xolair).

Dosage and administration: single-dose; subcutaneous injection in the deltoid region of the upper arm.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand the study and provide written voluntarily, and comply with the requirements;
  2. Healthy Chinese subjects aged 18-50 years, male or female;
  3. Normal or abnormal but without clinical significance reports of physical examinations, vital signs, clinical laboratory tests and others.

Exclusion criteria

Exclusion Criteria:

  1. Surgery history within 6 months prior to screening or any surgery schedule during the study;
  2. Last visit in previous drug clinical trial within 3 months prior to screening;
  3. Acute diseases occur or receive any medication during the screening period;
  4. Other conditions unsuitable for the study confirmed by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    JYB1904/JYB1904 Placebo

    single-dose; subcutaneous injection in the deltoid region of the upper arm.

    Drug: JYB1904 · Drug: JYB1904 Placebo

  • Active comparator
    Omalizumab

    single-dose; subcutaneous injection in the deltoid region of the upper arm.

    Drug: Omalizumab

Interventions

  • Dosage form: injection, solution; Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.

  • Dosage form: injection, powder, lyophilized, for solution; Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.

    Also known as: Xolair

  • DrugJYB1904 Placebo

    Dosage form: injection, solution; Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Incidence and features of AEs assessed by CTCAE v5.0

    Time frame: Baseline through 168 days post-dose

Secondary outcomes

  1. Serum concentrations of JYB1904 and Omalizumab

    Serum JYB1904 and Omalizumab assessed by pre-specified methods, and related pharmacokinetic parameters analysis

    Time frame: Baseline through 168 days post-dose

  2. Serum concentrations of total/free IgE

    Serum total/free IgE assessed by a pre-specified method, and related pharmacodynamic parameters analysis

    Time frame: Baseline through 168 days post-dose

  3. Serum concentrations of anti-drug antibody (ADA) and neutralizing antibody (Nab)

    Serum ADA and Nab assessed by pre-specified methods, and related immunogenic features analysis

    Time frame: Baseline through 168 days post-dose

07

Study locations

1 site
  • Shulan (Hangzhou) Hospital
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jan 2023, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2022
First posted
Jul 8, 2022
StartActual
May 7, 2022
Primary completionActual
Jan 10, 2023
CompletionActual
Jan 10, 2023
Last update
Jun 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05449535
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Jul 8, 2022
Start date
May 7, 2022
Primary completion
Jan 10, 2023
Completion
Jan 10, 2023
Last update
Jun 27, 2023

Study contacts

Guiling Chen, MD
principal investigator · Shulan (Hangzhou) Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozureprubart

Start the discussion